|Articles|November 15, 2022
Utilizing Automated High-Throughput SEC Native Mass Spectrometry for mAb Screening
Author(s)Agilent Technologies
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
FDA Fast Tracks Innovent’s Trispecific Antibody for Multiple Myeloma
2
Industrial-Scale Cell Therapy Automation Gains Traction with New Cellares Funding
3
HHS Releases New Guidance on Lowering Prescription Drug Prices Through DTC Programs
4
FDA Priority Review of Subcutaneous Lecanemab Signals Shift in Alzheimer’s Treatment Delivery
5